Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286181 | 0.90 | MTNR1A (0.34) | KMT2AFNTAFNTBMTNR1AMTNR1B | |
| SCHEMBL4285366 | 0.82 | HSP90AA1 (0.38) | KMT2ASMN1; SMN2MEN1KDM4EALDH1A1 | |
| SCHEMBL4289498 | 0.81 | TLR7 (0.39) | — | |
| SCHEMBL8118670 | 0.80 | PARP1 (0.49) | KMT2AMEN1 | |
| SCHEMBL4282219 | 0.79 | RAB9A (0.38) | SMN1; SMN2KDM4E | |
| SCHEMBL4287420 | 0.79 | S1PR4 (0.38) | KMT2AFNTAFNTBMEN1KDM4E | |
| SCHEMBL4285550 | 0.77 | MEN1 (0.40) | KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL4297009 | 0.75 | KDM4E (0.47) | KMT2AMEN1KDM4EALDH1A1NPSR1 | |
| SCHEMBL4285755 | 0.74 | KDM4E (0.51) | KMT2ASMN1; SMN2MEN1KDM4EALDH1A1 | |
| SCHEMBL4284003 | 0.74 | HCRTR1 (0.41) | SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KMT2A 1049/4885SMN1; SMN2 4811/4885FNTA 1157/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KMT2A 1049/4885SMN1; SMN2 4811/4885FNTA 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.